FULCRUM THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: Election Class III Directors, nominated by our Board of Directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders: Kate Haviland

FULCRUM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Kate Haviland”): 33,203,495 for, 13,016,576 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 72% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 1,436,899 for, 6,420,594 withheld.

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

Description as filed by funds: Election Class III Directors, nominated by our Board of Directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders: Katina Dorton

FULCRUM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Katina Dorton”): 44,618,582 for, 1,601,489 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 7,750,334 for, 107,159 withheld.

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

Description as filed by funds: Election Class III Directors, nominated by our Board of Directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders: Robert J. Gould

FULCRUM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Robert J. Gould”): 43,847,378 for, 2,372,693 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 7,706,625 for, 150,868 withheld.

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

Description as filed by funds: A non-binding advisory vote on executive compensation;

FULCRUM THERAPEUTICS INC.’s own tally for this item (“Fulcrum's stockholders approved, on a non-binding advisory basis, the compensation of Fulcrum's named executive officers.”): 46,099,800 for, 111,967 against — passed, per its Form 8-K filed June 27, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “b) Fulcrum's stockholders approved, on a non-binding advisory basis, the compensation of Fulcrum's named executive officers.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 43 managers: 7,936,621 for, 1,166 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 98 managers: 37,645,584 for, 17,917 against, 24,025 1 year. Showing the 25 largest; see all in the interactive database.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 42 managers: 7,821,390 1 year, 36,103 3 year. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 91 managers: 27,134 for, 386 against, 24,665,541 1 year, 187,464 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

FULCRUM THERAPEUTICS INC.’s own tally for this item (“Fulcrum's stockholders ratified the selection of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of the stockholders' vote with respect to ”): 49,513,190 for, 22,808 against — passed, per its Form 8-K filed June 27, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Fulcrum's stockholders ratified the selection of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 7,856,327 for, 1,166 against.

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.